15.42 0.00 (0.00%)
After hours: 4:51PM EDT
|Bid||15.43 x 1300|
|Ask||15.44 x 4000|
|Day's Range||15.24 - 15.69|
|52 Week Range||13.24 - 19.56|
|Beta (3Y Monthly)||1.58|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 5, 2019 - Aug 9, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.22|
SAN DIEGO, May 22, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that argenx has selected a second target under the collaboration and license agreement the companies announced in February 2019. The second target selected for development by argenx is human complement factor C2 associated with the product candidate ARGX-117, which is being developed to treat severe autoimmune diseases. Halozyme will receive a $10 million milestone payment during the current quarter from argenx for this target nomination and potential future payments of up to $160 million subject to achievement of specified development, regulatory and sales-based milestones.
SAN DIEGO , May 13, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in the Bank of America ...
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 0.00% and -20.23%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the San Diego-based company said it had profit of 1 cent. The results matched Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
- Revenue of $56.9 Million Compared to $30.9 Million in Prior-year Period - - ENHANZE® Partner Receives FDA Approval for Subcutaneous Formulation of Herceptin® - - Positive Phase 3 Trial Results Announced ...
Halozyme Therapeutics Inc NASDAQ/NGS:HALOView full report here! Summary * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for HALO with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $3.05 billion over the last one-month into ETFs that hold HALO are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
NEW YORK, NY / ACCESSWIRE / May 7, 2019 / Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 7, 2019 at 4:30 PM ...
SAN DIEGO, May 6, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the appointment of biotechnology and pharmaceutical industry expert Alison A. Armour, M.B. Ch.B., B.Sc., M.Sc., M.D., FRCR, FRCP, as senior vice president, research and development, effective immediately. In this role, she will report to Dr. Helen Torley, president and chief executive officer. Dr. Armour will lead Halozyme's research, clinical development, regulatory, safety and pharmacovigilance efforts.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you own shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) then it's worth thinking about how it...
Before we spend days researching a stock idea we'd like to take a look at how hedge funds and billionaire investors recently traded that stock. S&P 500 Index ETF (SPY) lost 13.5% in the fourth quarter. Seven out of 11 industry groups in the S&P 500 Index were down more than 20% from their 52-week […]
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO , April 23, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference ...
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be remiss not...
Using recent actions and grades from TheStreet's Quant Ratings and layering on technical analysis of the charts of those stocks, Trifecta Stocks identifies five names each Friday that look bearish. While we will not be weighing in with fundamental analysis we hope this piece will give investors interested in stocks on the way down a good starting point to do further homework on the names. recently was downgraded to Sell with a D+ rating by TheStreet's Quant Ratings.
SAN DIEGO , March 4, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in two upcoming investor ...
SAN DIEGO, Feb. 28, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that Genentech, a member of the Roche Group, has received approval from the U.S. Food and Drug Administration (FDA) for Herceptin Hylecta™, a subcutaneous fixed-dose combination of trastuzumab and hyaluronidase-oysk. Herceptin Hylecta™ is approved for the treatment of certain people with HER2-positive early breast cancer (node-positive, or node-negative and ER/PR-negative or with one high-risk feature) in combination with chemotherapy and HER2-positive metastatic breast cancer in combination with paclitaxel or alone in people who have received one or more chemotherapy regimens for metastatic disease.
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 50.00% and 1.65%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO (AP) _ Halozyme Therapeutics Inc. (HALO) on Thursday reported a fourth-quarter loss of $2.1 million, after reporting a profit in the same period a year earlier. The results topped Wall Street expectations. The biopharmaceutical company posted revenue of $60.2 million in the period, also beating Street forecasts.
- ENHANZE® Technology Licensed to argenx for up to Three Targets, Including Named target FcRn, Resulting in Upfront Payment of $30 Million - - 2019 Guidance Raised for Net Revenue and Year End Cash Balance ...